Buy & Sell Archer-Daniels-Midland Co (ADM) – Archer-Daniels-Midland Co Price Today
Aura AI Summary
Key Stats
- $39.00BMarket Cap
- Consumer StaplesSector
- -9.32%3M Drawdown
- $49.03BEnterprise Value
- 2.57%Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 68 daysTypical Hold Time
Archer-Daniels-Midland Co (ADM) is currently valued at a market capitalization of $39.00B, with an enterprise value of $49.03B. Over the past 52 weeks, Archer-Daniels-Midland Co has traded between a low of $47.42 and a high of $84.11, highlighting its annual price range. Over the past three months, Archer-Daniels-Midland Co has recorded a drawdown of -9.32%, reflecting recent price volatility. Archer-Daniels-Midland Co offers a dividend yield of 2.57%, with the most recent dividend of $0.52 paid on 20 May 26. On average, investors hold Archer-Daniels-Midland Co for approximately 68 days, indicating typical investor behavior on the platform.
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Most Recent News
Tesla's robotaxi fleet shrinks amid safety concerns; SpaceX IPO filing hints at major equity moves.
Tesla has reduced its robotaxi fleet to about 20 vehicles despite expanding the Austin service area, raising safety concerns from former engineers. Meanwhile, SpaceX updated its IPO filing, indicating a lock-in period for Musk's shares and potential ...

AI boom drives strong earnings beats, policy debates, and major tech moves worldwide
Recent financial reports show strong earnings beats driven by surging demand for artificial intelligence (AI) technologies, with companies like ServiceTitan, Palo Alto Networks, and CrowdStrike exceeding revenue and earnings estimates. Policymakers i...

Foundayo leads to significant weight loss in menopausal women, including those with type 2 diabetes, in clinical trials.
Eli Lilly's Foundayo (orforglipron) showed significant weight loss results in women across all menopause stages in the ATTAIN-1 and ATTAIN-2 trials, including those with type 2 diabetes. Women lost up to 30.4 lbs (14.4%) in perimenopause and up to 28...
